SUBSCRIBE
SUBSCRIBE

Eisai Inc.

NEWS
Genetown
Controversy Surrounds Biogen and Eisai’s Alzheimer’s Drug Aducanumab
Biogen and Tokyo-based development partner Eisai are embroiled in controversy surrounding their investigational Alzheimer’s drug, aducanumab.
November 4, 2020
 · 
2 min read
 · 
Heather McKenzie
Pharm Country
Morgan Stanley Global Healthcare Conference Update: Lilly, Amgen and Biogen
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
September 13, 2018
 · 
3 min read
 · 
Mark Terry
Load More
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Pharm Country
Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024
January 18, 2024
 · 
24 min read
Pharm Country
Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024
January 16, 2024
 · 
25 min read
Angle PLC - Contract announcement with Eisai Inc.
January 2, 2024
 · 
3 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
December 20, 2023
 · 
2 min read
Drug Development
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
December 8, 2023
 · 
73 min read
Business
Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today
November 7, 2023
 · 
6 min read
Genetown
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results & Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The CTAD Conference
October 25, 2023
 · 
27 min read
Drug Development
Eisai to Present New Data From LEQEMBI® (lecanemab-irmb) Phase 3 Clarity AD Study and Other Alzheimer’s Disease Pipeline Research at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 15, 2023
 · 
21 min read
Pharm Country
Eisai to Present Research From Oncology Portfolio and Pipeline at ESMO Congress 2023
October 11, 2023
 · 
31 min read
Drug Development
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
September 22, 2023
 · 
72 min read
Load More